BRAIN IPO: End of the stabilisation period and exercise of the Greenshoe Option

In connection with the BRAIN IPO, ODDO SEYDLER BANK AG was entitled, as stabilisation manager, to carry out measures to support the stock market price of BRAIN shares (stabilisation measures) until the thirtieth calendar day after the first day of trading of the shares, which was on February 9, 2016. Stabilisation measures were taken only to a small extent on February 9, 2016, the first day of the stabilisation period. They took place within a price range of 8.90 Euros and 9.00 Euros. The respective notice pursuant to article 9(3) of Commission Regulation (EC) No 2273/2003 of 22 December 2003 can be downloaded from the website of BRAIN AG at www.brain-biotech.de/en/investor-relations/ipo.

“The outcome of the stabilisation period and the positive share price development since the start of trading show that our shares have been sustainably placed in the capital market. Also, this confirms the trust that our investors place in the long-term growth potential of BRAIN AG and the field of bioeconomy in general. Our IPO project is now successfully concluded with the exercise of the Greenshoe Option”, says Dr Jürgen Eck, CEO of BRAIN AG. “This motivates us even more to take advantage of the tremendous potential of the bioeconomy while we continue to drive forward and expand our industrialisation strategy.”

+++ENDS+++

About BRAIN BRAIN is one of Europe’s leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this “Toolbox of Nature” are successfully applied in the chemistry, the cosmetics and the food industries. Today, BRAIN’s business model is based on two pillars – “BioScience” and “BioIndustrial”. The first pillar, “BioScience”, comprises its – frequently exclusive – collaboration business with industrial partners. The second pillar “BioIndustrial” comprises the development and commercialisation of BRAIN’s own products and active product components. Further information is available at www.brain-biotech.de/en

Disclaimer This publication does not constitute an offer to sell, or the solicitation of an offer to buy or subscribe for any securities. The public offer of shares of B.R.A.I.N. Biotechnology Research And Information Network AG is already concluded. This release is not for publication, release or distribution in the United States of America, Canada, Australia or Japan. This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.